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A B S T R A C T
Adults with medical multimorbidity (≥2 chronic conditions) present challenges for health care systems to
provide coordinated care. Substance use can complicate the management of chronic medical conditions, but
little research has focused on the intersection of medical multimorbidity and substance use. This study uses
cross-sectional analysis of 115,335 adult respondents of the 2012–2014 administrations of the National Survey
on Drug Use and Health to estimate the prevalence and correlates of past-year drug use among adults with
multimorbidity. The prevalence of past-year drug use was compared between individuals reporting 0, 1, and≥2
chronic medical conditions. We used multivariable logistic regression to determine correlates of past-year drug
use among adults with ≥2 chronic medical conditions. 53.1% reported no chronic conditions, 29.5% reported
one chronic condition, and 17.4% reported≥2 chronic conditions. Past-year drug use was reported by 18.3% of
those with no chronic conditions, 14.8% with 1 chronic condition, and 11.6% with ≥2 chronic conditions.
Cannabis and opioid analgesics (nonmedical use) were the most common drugs used across all three groups. In
the adjusted model, among adults with medical multimorbidity, adults with past-year drug use were more likely
to be younger, male, have lower income, and report current tobacco use, alcohol dependence, past-year de-
pression, and having received mental health treatment in the past year. In this national cohort, fewer adults with
multimorbidity reported substance use compared to adults with no or one chronic condition, however, this
population with high multimorbidity may be particularly vulnerable to the negative effects of drug use.
1. Introduction
Adults with medical multimorbidity, usually defined as ≥2 con-
current chronic conditions (Fortin et al., 2012; Wallace et al., 2015),
have high rates of healthcare utilization and associated costs (Lehnert
et al., 2011; Lochner and Cox, 2013). In addition to often receiving
poorly coordinated care (Boyd and Fortin, 2010), people with medical
multimorbidity experience the consequences associated with having
multiple chronic conditions including adverse effects from treatments
or interventions, disability, and death (American Geriatrics Society,
2012). In addition, living with medical multimorbidity often includes
taking multiple prescribed medications and careful monitoring of in-
dividual diseases. Substance use can have profound negative effects on
chronic diseases, therefore drug use and substance use disorder (SUD)
must be considered when developing effective care for the increasing
number of adults with medical multimorbidity (Paez et al., 2009).
Use of various psychoactive drugs is associated with a wide range of
physiologic effects that can affect the cardiovascular, gastrointestinal,
hematological, pulmonary, and neurological systems, and therefore
influence existing chronic disease and complicate management (Center
for Substance Abuse Treatment, 2006). SUDs themselves are considered
chronic diseases with known physiological changes in the brain and
need ongoing treatment and relapse prevention (Han and Moore,
2018). Therefore, the interaction of substance use with chronic medical
disease can lead to poor treatment outcomes for both SUDs and chronic
medical conditions.
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Many adults who are in treatment for SUD receive fragmented
medical care for their other chronic conditions (Gourevitch et al.,
2007), and unhealthy substance use often goes undiagnosed and un-
recognized by primary care physicians (Saitz et al., 1997). The ability to
manage chronic diseases depends on the awareness of substance use
and its possible effects on chronic medical diseases. However, few
studies have focused on the intersection of chronic medical disease and
drug use, and there are no studies that estimate the prevalence of drug
use among adults with multiple chronic conditions. Therefore, the ob-
jective for this study was to use cross-sectional data from a nationally
representative sample of adults in the United States (US) to estimate the
prevalence of drug use among adults with chronic medical diseases, and
to determine demographic and behavioral correlates of drug use among
adults with medical multimorbidity.
2. Methods
2.1. Data source and study sample
This study aggregated data from three cohorts (years 2012, 2013,
and 2014) of the National Survey on Drug Use and Health (NSDUH), an
annual cross-sectional survey of individuals in the US (Substance Abuse
and Mental Health Services Administration [SAMHSA], 2018). A dif-
ferent cross-section of non-institutionalized respondents is sampled
each year and therefore each cohort is independent of each other.
NSDUH is a nationally representative sample of individuals living in the
US (all fifty US states and the District of Columbia) and the sample was
achieved by the following methods: census tracts were first chosen
within each state, then sections in each tract were selected, then
households, and then respondents were selected for the sample each
year. Surveys were administered through computer-assisted inter-
viewing—conducted by an interviewer and audio computer-assisted
self-interviewing (ACASI). Sampling weights were provided by NSDUH
to address individual and unit-level non-response. Weights were ad-
justed to ensure that approximations are consistent with estimates
provided by the US Census Bureau. Detailed information regarding the
NSDUH survey and its sampling methods can be found elsewhere
(SAMHSA, 2018). The weighted interview response rates for NSDUH
years 2012 through 2014 was 71.7–73.0%, and missing or incomplete
data were revised by imputation.
2.2. Definitions
The NSDUH survey asks respondents if they had ever been informed
by a doctor or other medical professional that they have ever had the
following 12 medical diseases: asthma, bronchitis, cirrhosis of the liver,
diabetes, heart disease, hepatitis, hypertension (high blood pressure),
lung cancer, HIV/AIDS, sleep apnea, stroke, and ulcers. These medical
diseases are frequently considered chronic medical conditions, and are
included in either the validated Katz chronic disease comorbidity
questionnaire (Katz et al., 1996)15 or the Hierarchical Condition Cate-
gory system (Pope et al., 2004) and obstructive sleep apnea, which is
recognized as one of the most prevalent chronic respiratory disorders
(Lee and McNicholas, 2011) and therefore included in our analysis.
Medical multimorbidity is defined in the literature as 2 or more chronic
diseases (Fortin et al., 2012; Wallace et al., 2015). Using the above
conditions to study medical multimorbidity (≥2 chronic conditions)
with the NSDUH has been performed in other studies (Stanton et al.,
2016).
Drug use was assessed by NSDUH by self-report of cannabis (mar-
ijuana and hashish), cocaine (including crack), heroin, inhalants, hal-
lucinogens, and nonmedical use of prescription medications (including
opioids, tranquilizers, stimulants, and sedatives). Nonmedical use of
prescription medications was defined as use of a drug that was not
prescribed or used for the experience or feeling it caused. Nicotine
dependence was defined based on dependence criteria of the Nicotine
Dependence Syndrome Scale (NDSS) (Shiffman et al., 2004) and alcohol
dependence was defined by the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric
Association, 1994). SUDs were determined by participant responses to a
series of questions that determined if criteria would meet DSM-IV abuse
or dependence (American Psychiatric Association, 1994) categories for
each drug. While NSDUH is not a diagnostic interview, this method
provided a proxy diagnosis.
2.3. Statistical analyses
Analyses include all respondents aged 18 and older. We aggregated
data from the three separate cohort years into a single cross-section to
be able to increase power for examining associations between variables
with low prevalence (i.e., use of various drugs among those with mul-
timorbidity). We first examined bivariable associations between de-
mographic characteristics and number of self-reported conditions (i.e.,
0, 1, ≥2). Demographic measures included age (i.e., 18–34, 35–49,
50–64, and≥65), sex, race/ethnicity (i.e., non-Hispanic white, African
American, Asian, Hispanic of any race, and other), education level
(i.e., < high school, high school, some college, college or more), total
family income (i.e., < $20,000, $20,000–$49,999, $50,000–$74,000,
≥$75,000), marital status (i.e., married, widowed, divorced or sepa-
rated, never married). NSDUH only provides pre-coded categorical re-
sponses for the age and income variables, and therefore could not be
analyzed as a continuous variable. Tobacco use (past month, year),
nicotine dependence, alcohol use (past month, year), alcohol depen-
dence, self-reported overall health (i.e., excellent, very good, good,
fair), and self-reported mental health problems in the past-year (i.e.,
major depressive episode based on DSM IV criteria, self-reported an-
xiety, respondents who received mental health treatment) were also
compared among adults reporting 0, 1, and ≥2 chronic conditions.
Bivariable analyses was also performed comparing past-year drug
use and diagnosed substance use disorder for adults with 0, 1, and ≥2
chronic conditions. We evaluated correlates of past-year drug use
among adults with medical multimorbidity using binary logistic re-
gression. We first estimated odds of each covariate separately, gen-
erating unadjusted odds ratios (ORs). We then fit covariates simulta-
neously using multiple logistic regression. The adjusted ORs (AORs)
represent the odds of each category with all else in the model being
equal. All analyses were weighted as part of NSDUH to account for the
complex survey design and to obtain accurate standard errors for esti-
mates at the population level. More detailed information regarding the
development of analysis weights are found elsewhere (Center for
Behavioral Health Statistics and Quality, 2017). Since our analyses
utilized data from 3 cohorts, we divided the weights by 3 to obtain
nationally representative estimates. Stata SE 13 (Stata, 2013) was used
for all analyses, and survey (“svy”) commands were utilized to provide
accurate standard errors using Taylor series estimation methods
(Heeringa et al., 2010). Secondary analysis of this publically available
data was exempt for review by the New York University Langone
Medical Center Institutional Review Board.
3. Results
The analytic sample included 115,335 respondents. Chronic medical
conditions were common among respondents with weighted percen-
tages of 29.5% of adults reporting 1 chronic condition and 17.4% re-
porting 2 or more conditions, and therefore 46.9% reported at least 1
chronic condition and 53.1% reported no chronic conditions (Table 1).
Most adults with medical multimorbidity were middle-aged
(50–64 years of age) and older adults (≥65 years old), while younger
adults (18–34 years of age) were more likely to report no chronic
conditions (p < 0.001). Compared with adults reporting no chronic
conditions, adults with medical multimorbidity were also more likely to
be non-Hispanic white, less educated, married, have nicotine
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dependence, drink alcohol less frequently, report having worse health
status, and more likely to have depression, anxiety, and need mental
health treatment in the past year (p < 0.001 for all comparisons).
Table 2 presents frequencies and weighted percentages of specific
drugs used by 0, 1 or≥2 chronic conditions. Overall, 16.1% of the full
study sample reported past-year use of an illegal drug or cannabis and
2.6% reported meeting criteria for a SUD. The most common drug used
in the past-year was cannabis, and cannabis use disorder was the most
common SUD. Nonmedical use of opioid analgesics was the next-most
common and opioid-related SUD was the second most common SUD.
Among all adults with chronic conditions, past-year drug use was re-
ported by 14.8% with 1 chronic condition and 11.6% with ≥2 condi-
tions, and drug use was considerably higher among adults with no
chronic conditions (18.3%) (p < 0.001 for all comparisons). Among
adults reporting no chronic conditions, 5.5% used ≥2 drugs, while
4.3% of adults with 1 chronic disease and 3.2% of adults with ≥2
chronic diseases reported use of> 1 drug in the past year (p < 0.001).
Criteria for past-year SUD was met by 2.4% with 1 chronic condition
and 2.1% with ≥2 conditions, and 2.9% of adults with no chronic
conditions (p < 0.001).
Table 3 presents results from the multivariable logistic regression
model with past-year drug use as the outcome variable for adults with
medical multimorbidity (n=13,575). Results from the adjusted model
suggest that among adults with multimorbidity, odds of past-year drug
use decreased with increasing age (AOR 0.17 for adults≥65, AOR 0.46
for adults 50–64, and AOR 0.57 for adults 35–49, all p < 0.001 with
adults 18–34 as the comparison) and for females (AOR 0.52,
p < 0.001). For race/ethnicity, compared to whites non-Hispanic
Table 1
Sample characteristics by number of chronic conditions, % (n) – United States 2012–2014a.
Number of chronic conditions
0 chronic conditions 1 chronic condition ≥2 chronic conditions p-Value
n % (95% CI) n % (95% CI) n % (95% CI)
Characteristic 72,341 53.1% (52.6, 53.7) 29,419 29.5% (29.0, 30.0) 13,575 17.4% (17.0, 17.8)
Age group
(years of age)
18–34 49,318 41.3 (40.6, 42.0) 14,634 21.9 (21.3, 22.5) 4083 10.7 (10.2, 11.2) < 0.001
35–49 15,365 28.9 (28.4, 29.5) 7051 23.6 (22.8, 24.4) 3406 18.3 (17.5, 19.1) < 0.001
50–64 5435 20.6 (19.9, 21.4) 4450 29.8 (28.8, 30.9) 3215 35.1 (33.7, 36.4) < 0.001
≥65 2223 9.1 (8.7, 9.6) 3284 24.7 (23.8, 25.6) 2871 36.0 (34.6, 37.3) < 0.001
Sex
Male 33,975 48.0 (47.4, 48.5) 13,470 48.6 (47.8, 49.4) 5899 47.0 (45.7, 48.4) 0.12
Female 38,366 52.0 (51.5, 52.6) 15,949 51.4 (50.6, 52.2) 7676 53.0 (51.6, 54.3) 0.12
Race/ethnicity
Non-Hispanic White 43,301 62.5 (61.8, 63.2) 18,894 67.8 (66.6, 69.0) 9565 74.0 (72.7, 75.2) < 0.001
Non-Hispanic African American 8468 10.5 (10.0, 11.0) 4236 13.8 (13.0, 14.6) 1624 11.6 (10.6, 12.6) < 0.001
Hispanic 13,370 18.4 (17.9, 19.0) 3898 12.2 (11.5, 12.9) 1304 8.9 (8.2, 9.7) < 0.001
Non-Hispanic Asian 3710 6.4 (6.0, 6.8) 879 3.7 (3.2, 4.3) 313 3.0 (2.4, 3.6) < 0.001
Other 3492 2.2 (2.0, 2.3) 1512 2.6 (2.3, 2.8) 769 2.6 (2.3, 3.0) < 0.001
Education
<High school 10,602 13.4 (13.0, 13.9) 4251 14.0 (13.4, 14.7) 1920 13.2 (12.3, 14.0) < 0.001
High school 22,370 27.8 (27.2, 28.3) 9418 31.1 (30.3, 32.0) 4359 31.0 (30.0, 32.1) < 0.001
Some college 21,584 27.3 (26.7, 27.8) 8645 25.9 (25.1, 26.7) 3936 28.0 (26.9, 29.1) < 0.001
College or more 17,785 31.6 (30.9, 32.3) 7105 28.9 (28.0, 29.9) 3360 27.8 (26.7, 28.9) < 0.001
Total family income
<$20,000 42,615 44.5 (43.8, 45.2) 15,851 41.6 (40.7, 42.6) 6854 42.3 (41.2, 43.5) < 0.001
$20–$49,999 19,439 31.8 (31.2, 32.4) 8535 34.0 (33.0, 35.0) 4263 34.7 (33.5, 36.0) < 0.001
$50,000–$74,999 5345 11.5 (11.1, 12.0) 2596 11.4 (10.8, 12.1) 1260 11.1 (10.4, 11.9) < 0.001
≥$75,000 4942 12.2 (11.6, 12.8) 2437 13.0 (12.3, 13.7) 1198 11.8 (11.0, 12.7) < 0.001
Marital status
Married 25,045 49.8 (49.1, 50.4) 11,871 54.5 (53.6, 55.5) 6363 56.2 (54.8, 57.6) < 0.001
Widowed 1007 3.4 (3.1, 3.6) 1218 8.0 (7.5, 8.6) 952 10.5 (9.7, 11.4) < 0.001
Divorced or separated 6019 12.5 (12.1, 12.9) 3447 15.1 (14.5, 15.8) 2294 18.4 (17.6, 19.4) < 0.001
Never married 40,270 34.4 (33.8, 35.0) 12,883 22.3 (21.7, 23.0) 3966 14.8 (14.0, 15.7) < 0.001
Tobacco use
Past month use 24,715 29.4 (28.8, 30.1) 9667 26.5 (25.8, 27.3) 4175 24.4 (23.4, 25.4) < 0.001
Past year use 30,524 35.5 (34.9, 36.1) 11,663 31.2 (30.4, 32.1) 4887 27.9 (26.8, 29.0) < 0.001
Past year nicotine dependenceb 6997 8.6 (8.3, 9.0) 3125 8.6 (8.2, 9.1) 1760 10.2 (9.6, 10.9) < 0.001
Alcohol use
Past month use 43,742 60.0 (59.3, 60.7) 17,180 55.3 (54.4, 56.3) 7026 48.4 (47.1, 49.6) < 0.001
Past year use 55,110 74.1 (73.5, 74.8) 21,806 69.6 (68.6, 70.5) 9327 63.6 (62.2, 65.0) < 0.001
Past year alcohol Use, but not dependence 51,826 70.7 (70.1, 71.4) 20,483 66.2 (65.2, 67.1) 8741 60.7 (59.3, 62.1) < 0.001
Past year alcohol dependencec 3284 3.4 (3.2, 3.6) 1323 3.4 (3.1, 3.7) 566 2.9 (2.6, 3.3) < 0.001
Overall Health
Excellent 21,590 30.1 (29.5, 30.7) 5141 15.6 (14.9, 16.3) 1102 7.0 (6.4, 7.6) < 0.001
Very good 29,479 39.2 (38.7, 39.7) 11,395 37.0 (36.1, 37.8) 3772 26.2 (25.0, 27.4) < 0.001
Good 16,793 23.3 (22.8, 23.9) 9055 32.1 (31.3, 33.0) 4875 36.8 (35.6, 38.0) < 0.001
Fair/poor 4467 7.3 (7.0, 7.6) 3820 15.3 (14.6, 16.1) 3821 30.0 (28.9, 31.2) < 0.001
Mental health
Past year major depressive episodec 4894 5.7 (5.5, 6.0) 2530 6.5 (6.1, 7.0) 1878 10.9 (10.2, 11.6) < 0.001
Past year anxiety 4511 5.7 (5.4, 5.9) 2272 6.0 (5.6, 6.4) 1807 10.4 (9.7, 11.1) < 0.001
Received mental health treatment in past year 8672 12.0 (11.6, 12.4) 4811 15.3 (14.7, 15.9) 3521 23.1 (22.0, 24.2) < 0.001
a All percentages are weighted.
b Based on the Nicotine Dependence Syndrome Scale (NDSS).
c Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
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African Americans (AOR 0.71, p < 0.05) and Asians (AOR 0.48,
p < 0.05) also had lower odds for past-year drug use. For family in-
come, compared to incomes<$20,000, higher incomes (AOR 0.53 for
incomes ≥$75,000/year, p < 0.001; AOR 0.64 for incomes
$50,000–$74,999, p < 0.01; AOR 0.62 for incomes $20,000–$49,999,
p < 0.001) were associated with lower odds for past-year drug use. In
contrast, respondents reporting past-month use of tobacco (AOR 2.45,
p < 0.001), alcohol use (not meeting criteria for dependence) (AOR
3.33, p < 0.001), alcohol dependence (AOR 10.19, p < 0.001), past-
year major depressive episode (AOR 1.28, p < 0.05), and received
mental health treatment in the past year (AOR 1.79, p < 0.001) all had
higher odds of reporting past-year drug use.
4. Discussion
In this large, nationally representative survey, we estimated the
prevalence of past-year drug use among adults without chronic medical
conditions and among those with one and two or more chronic medical
conditions (i.e., medical multimorbidity). While the prevalence of past-
year drug use was lower among adults with medical multimorbidity,
compared to adults with no chronic conditions, nearly 12% of adults
with multimorbidity reported engaging in past-year drug use. The lower
prevalence of drug use among adults with multimorbidity may be due
to both the fact that younger adults were more likely to engage in drug
use and less likely to have chronic medical conditions, and some of
those with multimorbidity may have stopped using drugs because of
their morbidities (Naimi et al., 2016). In alcohol studies for example,
the “sick quitter” hypothesis proposes that adults may stop drinking due
to medical illness, hospitalizations, or declining health, and therefore
this group is not included as individuals with alcohol-related problems
even though alcohol may have contributed to their illnesses (Shaper
et al., 1988). A similar phenomenon is likely occurring in observational
studies with drug use including our study. However, we did find in
multivariable models that among adults with medical multimorbidity,
adults with alcohol dependence, current tobacco use, and adults with
mental health problems were more likely to have engaged in past year
drug use, and therefore be at particularly high risk for adverse effects of
drug use. This emphasizes the importance of including SUDs and
polysubstance use disorders to the multimorbidity framework as a
distinct clinical profile that necessitates further research to better care
for patients with complex multimorbid disease (Bhalla et al., 2017;
North et al., 2016).
The intersection of substance use and medical multimorbidity is
complex. Drug use has a wide array of physiologic effects on the body,
that may negatively impact existing chronic medical disease and com-
plicate its management. For example, cocaine use can impact both the
cardiovascular and cerebrovascular systems that can lead to stroke,
disability or sudden death, particularly among adults with pre-existing
disease (Center for Substance Abuse Treatment, 2006). Second, sub-
stance use can also complicate the clinical management of existing
chronic diseases. Studies have shown decreased adherence to anti-
retroviral therapy among adults with HIV who engage in active sub-
stance use (Pozner et al., 2005), and poor medication adherence for
adults with psychosis who used cannabis (Nijhawan et al., 2008). This
is particularly relevant for adults with medical multimorbidity, who
often have complex medication schedules that demand careful mon-
itoring and daily management. In addition, the complicated medical
care that adults with medical multimorbidity face places them at risk
for medication management mistakes as well as adverse drug effects
and interactions (Schoeler et al., 2017). This emphasizes the im-
portance of substance use screening for adults with chronic conditions.
In addition, since many adults in SUD treatment often have fragmented
primary care (Gourevitch et al., 2007), it is also important for SUD
treatment providers to screen and ensure medical comorbidities are
being managed.
In our study sample, cannabis was the most commonly used drug
among adults with chronic disease. This is not surprising since cannabis
is the most common drug used in the NSDUH study sample and given
more positive attitudes and policies related to cannabis use (Flaherty
et al., 2000; Gallup, 2018). Cannabis has been used and studied for
medical treatment of chronic diseases including HIV, multiple sclerosis,
chronic pain, seizure disorder, and other mental health disorders
(National Institute on Drug Abuse [NIDA], 2018). Although this study
cannot distinguish between medical use versus recreational use of
cannabis, using cannabis for these types of conditions may partially
explain its high prevalence use among adults with chronic disease (both
Table 2
Past-year drug use by number of chronic conditions, % (n) – United States 2012–2014a.
Number of chronic conditions
0 chronic conditions (n= 72,341) 1 chronic condition (n= 29,419) ≥2 chronic conditions (n= 13,575) p-Value
n % (95% CI) n % (95% CI) n % (95% CI)
Drug use category (past-year use)
Any drug 18,419 18.3 (17.9, 18.8) 6663 14.8 (14.2, 15.4) 2448 11.6 (10.8, 12.4) < 0.001
Any drug, excluding cannabis 8360 8.5 (8.2, 8.9) 3216 7.3 (6.9, 7.7) 1240 5.8 (5.3, 6.4) < 0.001
Cannabis 15,722 14.9 (14.5, 15.2) 5446 11.2 (10.7, 11.8) 1909 8.4 (7.8, 9.0) < 0.001
Cocaine 2101 2.1 (2.0, 2.3) 758 1.7 (1.5, 1.9) 266 1.2 (1.0, 1.4) < 0.001
Heroin 371 0.3 (0.3, 0.4) 145 0.3 (0.2, 0.3) 76 0.3 (0.2, 0.4) < 0.001
Opioid analgesics 4359 4.6 (4.4, 4.8) 1758 4.1 (3.8, 4.4) 764 3.4 (3.1, 3.8) < 0.001
Hallucinogens 2607 2.1 (2.0, 2.3) 788 1.3 (1.1, 1.5) 263 0.7 (0.6, 0.9) < 0.001
Tranquilizers/sedatives 2243 2.3 (2.2, 2.5) 976 2.3 (2.1, 2.6) 467 2.1 (1.8, 2.4) 0.36
Stimulants 1587 1.5 (1.3, 1.6) 558 1.0 (0.9, 1.1) 214 0.8 (0.7, 1.1) < 0.001
≥2 illegal drug use 6006 5.5 (5.3, 5.8) 2196 4.3 (4.1, 4.6) 804 3.2 (2.8, 3.6) < 0.001
Substance use disorder (past-year)
Any drug 3208 2.9 (2.7, 3.1) 1279 2.4 (2.2, 2.7) 509 2.1 (1.8, 2.4) < 0.001
Any drug, excluding cannabis 1399 1.4 (1.3, 1.6) 612 1.4 (1.2, 1.6) 292 1.3 (1.1, 1.5) 0.58
Cannabis 2124 1.7 (1.6, 1.8) 823 1.3 (1.1, 1.4) 266 1.0 (0.8, 1.2) < 0.001
Cocaine 328 0.4 (0.3, 0.5) 138 0.4 (0.3, 0.5) 81 0.4 (0.3, 0.6) 0.94
Heroin 255 0.2 (0.2, 0.3) 107 0.2 (0.1, 0.2) 59 0.2 (0.2, 0.3) 0.58
Opioid analgesics 762 0.8 (0.7, 0.9) 311 0.7 (0.6, 0.9) 175 0.8 (0.6, 1.0) 0.76
Hallucinogens 145 0.1 (0.1, 0.1) 53 0.1 (0.1, 0.1) 19 0.0 (0.0, 0.1) 0.07
Tranquilizers/sedatives 183 0.2 (0.1, 0.2) 110 0.2 (0.2, 0.3) 62 0.2 (0.2, 0.4) 0.25
Stimulants 187 0.2 (0.1, 0.3) 96 0.2 (0.1, 0.2) 43 0.2 (0.1, 0.3) 0.84
a All percentages are weighted.
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self-medicated or prescribed in states where it is legal) (NIDA, 2018).
The risks of cannabis have not been well-documented, particularly
among older adults with medical multimorbidity who may be at higher
risk for negative cardiovascular, pulmonary, and cognitive effects of
cannabis use (Han and Moore, 2018). Further study is needed to better
assess the benefits and risks of cannabis use for specific chronic diseases
and overall use by adults with medical multimorbidity.
The statistically significant correlates of past-year drug use among
adults with medical multimorbidity identified in this study include
younger age, male sex, low family income (< $20,000), current to-
bacco use, alcohol use and alcohol dependence, having had a major
depressive episode, and having received mental health treatment. The
demographic findings are similar to the overall results of NSDUH
among the general adult population for illegal drug use including
cannabis, such as adults with younger age and male sex having higher
rates of use (SAMHSA, 2018). However, our results are novel in that
they identify a potentially very high-risk population of adults with the
combination of medical multimorbidity with polysubstance use (drug,
alcohol, and/or tobacco use) and/or mental health disorders. The
strong association we found with alcohol dependence with concurrent
drug use among adults with medical multimorbidity is alarming. Un-
healthy alcohol use itself can cause, exacerbate, and complicate the
management of several chronic medical diseases (Park and Wu, 2017),
and therefore the combination of illegal drug use with alcohol use,
especially if used concurrently, can be particularly dangerous for adults
with existing chronic medical conditions. Further, the co-occurrence of
substance use and SUD with mental health illnesses are well docu-
mented (National Institute of Alcohol Abuse and Alcoholism, 2000),
and interventions for addressing patients with co-occurring conditions
have been developed and studied (Chapman et al., 2005). The added
mental health comorbidity is particularly important as one recent study
of 843,584 veterans in the VA system who had at least three visits to a
mental health clinic found 30.6% had co-occurring psychiatric and
SUDs (Bhalla et al., 2017). The added burden of polysubstance use
along with mental health problems highlights the need for a syndemic
framework for caring for patients with compound multimorbidity,
where the focus is how multiple health conditions are adversely af-
fected by behavioral, psychiatric, biological, and social conditions
Table 3
Correlates of past-year substance use among adults with medical multimorbiditya – United States 2012–2014.
Characteristic OR (95% CI) AOR (95% CI)
Age group
18–34 1.00 1.00
35–49 0.39‖ (0.34, 0.44) 0.57‖ (0.48, 0.69)
50–64 0.25‖ (0.21, 0.29) 0.46‖ (0.37, 0.57)
≥65 0.06‖ (0.04, 0.08) 0.17‖ (0.11, 0.25)
Sex
Male 1.00 1.00
Female 0.68‖ (0.60, 0.77) 0.52‖ (0.45, 0.61)
Race/ethnicity
Non-Hispanic White 1.00 1.00
Non-Hispanic African American 0.85 (0.69, 1.06) 0.71‡ (0.55, 0.92)
Hispanic 1.21 (0.94, 1.55) 0.94 (0.70, 1.26)
Non-Hispanic Asian 0.38§ (0.22, 0.66) 0.48‡ (0.26, 0.88)
Other 1.54‡ (1.08, 2.18) 1.12 (0.70, 1.81)
Education
<High school 1.00 1.00
High school 0.86 (0.68, 1.09) 0.81 (0.61, 1.09)
Some college 1.13 (0.93, 1.38) 1.08 (0.83, 1.41)
College or more 0.81 (0.65, 1.01) 1.08 (0.81, 1.44)
Total family income
<$20,000 1.00 1.00
$20,000–$49,999 0.57‖ (0.48, 0.67) 0.62‖ (0.50, 0.76)
$50,000–$74,999 0.60§ (0.45, 0.80) 0.64§ (0.47, 0.88)
≥$75,000 0.47‖ (0.36, 0.61) 0.45‖ (0.32, 0.63)
Marital status
Never married 1.00 1.00
Widowed 0.13‖ (0.09, 0.19) 0.57‡ (0.33, 0.98)
Divorced or separated 0.50‖ (0.41, 0.60) 0.80 (0.62, 1.04)
Married 0.23‖ (0.20, 0.27) 0.49‖ (0.39, 0.62)
Tobacco use
Past month use 4.57‖ (3.95, 5.29) 2.45‖ (2.05, 2.92)
Alcohol use
Past year alcohol use, but not dependence 3.96‖ (3.21, 4.90) 3.33‖ (2.62, 4.23)
Past year dependence 22.98‖ (17.26, 30.59) 10.19‖ (6.96, 14.94)
Overall health
Fair/poor 1.00 1.00
Good 0.86 (0.71, 1.04) 0.97 (0.65, 1.46)
Very good 0.85 (0.71, 1.03) 0.97 (0.76, 1.23)
Excellent 0.89 (0.65, 1.21) 0.97 (0.77, 1.22)
Mental health
Past year major depressive episodeb 2.94‖ (2.49, 3.47) 1.28‡ (1.02, 1.61)
Past year anxiety 2.78‖ (2.39, 3.24) 1.22 (0.95, 1.58)
Received mental health treatment in past year 2.48‖ (2.13, 2.90) 1.79‖ (1.40, 2.30)
a Multimorbidity defined as 2 or more of the following: asthma, bronchitis, cirrhosis of the liver, diabetes, heart disease, hepatitis, hypertension (high blood
pressure), lung cancer, HIV/AIDS, sleep apnea, stroke, and ulcers.
b Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
‡ p < 0.05.
§ p < 0.01.
‖ p < 0.001.
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(Bhugra and Ventriglio, 2017; Perry et al., 2015). The use of the syn-
demic framework can help identify intervention strategies to reduce
harms and improve the management of chronic disease for adults with
medical multimorbidity, polysubstance use, and mental health dis-
orders. In practice, one approach using this framework could include
the integration of primary care and chronic disease management into
SUD and mental health treatment settings and vice-versa.
There are important limitations to this study. First, the NSDUH re-
sponses are based on self-report and thus are subject to both recall and
social-desirability bias; although the survey attempts to limit the latter
via ACASI (SAMHSA, 2018). Second, the NSDUH does not assess when a
respondent first experienced or was diagnosed with a chronic medical
disease, but asks only for lifetime prevalence. Therefore, participants
may have had a chronic medical condition years before being surveyed
and that condition may have been resolved and not overlap with past-
year drug use. However, most of the conditions queried (i.e., hy-
pertension, sleep apnea, heart disease, cirrhosis, stroke) tend to be
lifelong. In addition, while the specific chronic diseases chosen in the
NSDUH study design were based on expert opinion of medical diseases
that are often related to substance use (SAMHSA, 2018), it does not
include many chronic medical diseases that are often asked in clinical
research and epidemiological studies to understand the burden of
chronic disease in specific populations. It also does not specify “heart
disease” further, thus this could include a wide range of cardiac dis-
eases. Therefore, the generalizability of this study is limited to the
specific chronic diseases asked of this study sample and how it was
asked. Also, assessing DSM SUD criteria via surveys can also be limited
as these are not full diagnostic interviews. Finally, our study classifies
users of drugs if the individual used in the past-year and therefore does
not distinguish between one-time use versus more frequent use, which
may potentially have different risks and consequences. To help address
this we did include substance use disorder in estimating substance use
among adults with chronic diseases.
5. Conclusions
This study estimates the use of drugs by adults with medical mul-
timorbidity and highlights areas that need to be better explored. Adults
with multimorbidity should be screened for substance use to identify
and treat unhealthy use, which can impact chronic disease. Further
study is needed to better delineate the risks and harms of specific drug
use not only on individual chronic diseases, but on individuals who live
with and manage multiple chronic conditions.
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